Clinical Trials Logo

Clinical Trial Summary

This is a case-control study that aims to build a predictive model for MAFLD based on machine learning.


Clinical Trial Description

Metabolic dysfunction-associated fatty liver disease (MAFLD) also known as non-alcoholic fatty liver disease (NAFLD), is one of the most prevalent liver diseases worldwide with high prevalence and economic burden, which affects 25% of global adult population. Despite extensive research on understanding the inner pathophysiology of MAFLD, it still keep growing with no approval therapy. Therefore, preventive measures are particularly important in diagnosing MAFLD. So far the liver biopsy is still the gold standard for diagnosis of MAFLD, however considering the invasive process and potential risks, it still has low acceptance for asymptomatic patients, thus non-invasive methods are necessary for this reason. The purpose of this study is to establish a prediction model to identify MAFLD patients, which can accurately predict whether the participants have MAFLD according to the relevant metabolic indicators of the participants, without the need for invasive examinations such as tissue biopsy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06061640
Study type Observational
Source The First Affiliated Hospital of Zhejiang Chinese Medical University
Contact
Status Active, not recruiting
Phase
Start date June 1, 2023
Completion date December 31, 2024